Chronic vaginitis. Subacute and chronic vaginitis
Conditions
Interventions
Intervention 1: Intervention group: Individuals in the intervention group will be treated with DBD plasma (produced by the ED DBD Plasma 3Medgroup, Germany) for 4 weeks (once a week, for 15 minutes ea
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 35 Years
Inclusion criteria
Inclusion criteria: Informed consent to participate in the study Age between 18 and 35 years old
Exclusion criteria
Exclusion criteria: Cervical cancer Immune system deficiency or infection with HIV and HPV Metabolic diseases Pregnancy Multi-Partner Having underlying chronic diseases (diabetes, hypertension, liver and kidney failure) People with abnormal Pap smears
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of clinical symptoms of chronic vaginitis. Timepoint: Assessment of the severity of clinical symptoms at the beginning of the study and one month after the start of treatment. Method of measurement: Questionnaire and clinical examination.;Satisfaction with treatment. Timepoint: Assessment of satisfaction with treatment at the beginning of the study and one month after the start of treatment. Method of measurement: Questionnaire in the form of: Satisfaction with treatment (from completely satisfied to completely dissatisfied). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNastaran Teymoorianfard
Shahid Beheshti University of Medical Sciences
Outcome results
None listed